Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Wolter

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA studyReinhard Dummer, Henry M Prince, Sean Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2018
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)Richard D Carvajal, Sophie Piperno-Neumann, Ellen Kapiteijn, et al.
Lancet (London, England)|June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH Miles Prince, Youn H Kim, Steven M Horwitz, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysisYoun H Kim, H Miles Prince, Sean Whittaker, et al.
International Journal of Cancer|February 19, 2014
Inherited variation in the PARP1 gene and survival from melanomaJohn R Davies, Rosalyn Jewell, Paul Affleck, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA studyReinhard Dummer, Henry M Prince, Sean Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2018
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)Richard D Carvajal, Sophie Piperno-Neumann, Ellen Kapiteijn, et al.
Lancet (London, England)|June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH Miles Prince, Youn H Kim, Steven M Horwitz, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysisYoun H Kim, H Miles Prince, Sean Whittaker, et al.
International Journal of Cancer|February 19, 2014
Inherited variation in the PARP1 gene and survival from melanomaJohn R Davies, Rosalyn Jewell, Paul Affleck, et al.
Pageof 6